For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stuart Connolly from McMaster University presented the findings.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.